As 6% topical solution, proved able to increase time to treatment failure (in a double-blind, placebo-controlled, phase III trial) in cutaneous metastases from breast cancer patientsRegistered and used in India, Colombia, and Germany for the treatment of visceral and cutaneous leishmaniasisTargets HIV-infected macrophages. The HIV protein Tat activates pro-survival PI3K/Akt pathway in primary human macrophages. Miltefosine acts by inhibiting the PI3K/Akt pathway, thus removing the infected macrophages from circulation, without affecting healthy cells. Here, TAT is linked to breast cancer.